DYNAMIC SAMPLE MAPPING NONINVASIVE ANALYZER APPARATUS AND METHOD OF USE THEREOF
A noninvasive analyzer apparatus and method of use thereof is described using a sample mapping phase to establish one or more analyzer/software parameters used in a subsequent individual and/or group specific data collection phase. For example, in the sample mapping phase distance between incident and collected light is varied as a function of time for collected noninvasive spectra. Spectra collected in the sample mapping phase are analyzed to determine a physiological property of the subject, such as dermal thickness, hydration, collagen density, epidermal thickness, and/or subcutaneous fat depth. Using the physiological property or measure thereof, the analyzer is optically reconfigured for the individual to yield subsequent spectra having enhanced features for noninvasive analyte property determination. Similarly, in the mapping and/or collection phase, the incident light is varied in time in terms of any of: sample probe position, incident light solid angle, incident light angle, depth of focus, energy, and/or intensity.
This application is:
-
- a continuation-in-part of U.S. patent application Ser. No. 13/941,389 filed Jul. 12, 2013, which:
- is a continuation-in-part of U.S. patent application Ser. No. 13/941,369 filed Jul. 12, 2013, which claims the benefit of U.S. provisional patent application No. 61/672,195 filed Jul. 16, 2012; and
- claims the benefit of U.S. provisional patent application No. 61/700,291 filed Sep. 12, 2012; and
- claims the benefit of U.S. provisional patent application No. 61/700,294 filed Sep. 12, 2012
- all of which are incorporated herein in their entirety by this reference thereto.
- a continuation-in-part of U.S. patent application Ser. No. 13/941,389 filed Jul. 12, 2013, which:
The present invention relates to a noninvasive analyzer using a sample mapping phase to generate instrumentation setup parameters followed by a subject specific data collection phase using the configured instrument.
DESCRIPTION OF THE RELATED ARTPatents and literature related to the current invention are summarized herein.
DiabetesDiabetes mellitus or diabetes is a chronic disease resulting in the improper production and/or use of insulin, a hormone that facilitates glucose uptake into cells. Diabetes is broadly categorized into four forms grouped by glucose concentration state: hyperinsulinemia (hypoglycemia), normal physiology, impaired glucose tolerance, and hypoinsulinemia (hyperglycemia).
Diabetics have increased risk in three broad categories: cardiovascular heart disease, retinopathy, and/or neuropathy. Complications of diabetes include: heart disease, stroke, high blood pressure, kidney disease, nerve disease and related amputations, retinopathy, diabetic ketoacidosis, skin conditions, gum disease, impotence, and/or fetal complications.
Diabetes is a common and increasingly prevalent disease. Currently, diabetes is a leading cause of death and disability worldwide. The World Health Organization estimates that the number of people with diabetes will grow to three hundred million by the year 2025.
Long term clinical studies show that the onset of diabetes related complications is significantly reduced through proper control of blood glucose concentrations, The Diabetes Control and Complications Trial Research Group, “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus”, N. Eng. J. of Med., 1993, vol. 329, pp. 977-986.
SkinThe structure of skin varies widely among individuals as well as between different skin sites on a single individual. The skin has layers, including: (1) a stratum corneum of flat, dehydrated, biologically inactive cell about 10 to 20 micrometers thick; (2) a stratified epidermis, of about 10 to 150 micrometers thickness, formed and continuously replenished by slow upward migration of keratinocyte cells from the germinative basal layer of the epidermis; (3) an underlying dermis of connective fibrous protein, such as collagen, and a blood supply, which form a layer of 0.5 to 4.0 millimeters in thickness with an average thickness of about 1.2 millimeters; and (4) a underlying fatty subcutaneous layer or adipose tissue.
Fiber Optic Sample BundleGarside, J., et. al., “Fiber Optic Illumination and Detection Patterns, Shapes, and Locations for use in Spectroscopic Analysis”, U.S. Pat. No. 6,411,373 (Jun. 25, 2002) describe software and algorithms to design fiber optic excitation and/or collection patterns in a sample probe.
Maruo, K., et. al., “Device for Non-Invasive Determination of Glucose Concentration in Blood”, European patent application no. EP 0843986 B1 (Mar. 24, 2004) described the use of light projecting fiber optics in the range of 0.1 to 2 millimeters from light receiving fiber optics at the contacted fiber optic bundle/sample interface.
Skin ThicknessRennert, J., et. al., “Non-Invasive Method of Determining Skin Thickness and Characterizing Layers of Skin Tissue In Vivo”, U.S. Pat. No. 6,456,870 B1 (Sep. 24, 2002) described the use of near-infrared absorbance spectra to determine overall thickness of skin tissue and layer-by-layer thickness of skin tissue.
Ruchti, T. L., et. al., “Classification System for Sex Determination and Tissue Characterization”, U.S. Pat. No. 6,493,566 B1 (Dec. 10, 2002) describe the near-infrared tissue measurements to yield predictions consisting of gender and one or more of thickness of a dermis, collagen content, and amount of subcutaneous fat.
Mattu, M., et. al., “Classification and Screening of Test Subjects According to Optical Thickness of Skin”, U.S. Pat. No. 6,738,652 B2 (May 18, 2004) describe the use of near-infrared reflectance measurements of skin to determine the optical thickness of skin through analysis of water, fat, and protein marker bands.
Sample Probe/Tissue ContactAbul-Haj, A., et. al., “Method and Apparatus for Noninvasive Targeting”, U.S. patent application no. US 2006/0217602 A1 (Sep. 28, 2006) describe a sample probe interface method and apparatus for targeting a tissue depth and/or pathlength that is used in conjunction with a noninvasive analyzer to control spectral variation.
Welch, J. M., et. al., “Method and Apparatus for Noninvasive Probe/Skin Tissue Contact Sensing”, WIPO International publication no. WO 2008/058014 A2 (May 15, 2008) describe a method and apparatus for determining proximity and/or contact of an optical probe with skin tissue.
Problem StatementWhat is needed is a noninvasive glucose concentration analyzer having precision and accuracy suitable for treatment of diabetes mellitus.
SUMMARY OF THE INVENTIONThe invention comprises a noninvasive analyzer apparatus having dynamic control of distance between a plurality of irradiation zones and a detection zone and a method of use thereof.
A more complete understanding of the present invention is derived by referring to the detailed description and claims when considered in connection with the Figures, wherein like reference numbers refer to similar items throughout the Figures.
Elements and steps in the figures are illustrated for simplicity and clarity and have not necessarily been rendered according to any particular sequence. For example, steps that are performed concurrently or in a different order are illustrated in the figures to help improve understanding of embodiments of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTSThe invention comprises an apparatus and method of use thereof for acquisition of noninvasive mapping spectra of skin and to reconfigure the apparatus based upon the mapping spectra for subsequent subject specific data collection.
For example, a near-infrared noninvasive analyzer is configured with a first optical configuration used to map an individual and/or group of individuals through use of mapping spectra. The mapping spectra are analyzed and used to reconfigure the optical setup of the analyzer to a second optical configuration suited to the individual and/or group of individuals. Subsequently, collection of noninvasive spectra of the individual and/or group of individuals is performed using the second optical configuration, which is preferably optimized to yield additional information based on the skin of the individual and/or group of individuals.
In another embodiment, a data processing system analyzes data from an analyzer to estimate and/or determine an analyte property, such as concentration using multiple types of data, such as from an external sensor, from two or more radial positions, and/or with two of more focusing depths.
In still another embodiment, an analyzer using light interrogates the sample using one or more of:
-
- a spatially resolved system;
- an incident light radial distance resolved system;
- a controllable and variable incident light solid angle system; and
- a controllable and variable incident light angle system;
- a time resolved system, where the times are greater than about 1, 10, 100, or 1000 microseconds;
- a picosecond timeframe resolved system, where times are less than about 1, 10, 100, or 1000 nanoseconds;
- collection of spectra with varying radial distances between incident light entering skin and detected light exiting the skin;
- an incident angle resolved system; and
- a collection angle resolved system.
- a spatially resolved system;
Data from the analyzer is analyzed using a data processing system capable of using the information inherent in the resolved system data.
In yet another embodiment, a data processing system uses interrelationships of chemistry based a-priori spectral information related to absorbance of a sample constituent and/or the effect of the environment, such as temperature, on the spectral information.
In yet still another embodiment, a data processing system uses a first mapping phase to set instrument control parameters for a particular subject, set of subjects, and/or class of subjects. Subsequently, the control parameters are used in a second data collection phase to collect spectra of the particular subject or class of subjects.
In still yet another embodiment, a data processing system uses information related to contact pressure on a tissue sample site.
In another embodiment, a data processing system uses a combination of any of:
-
- spatially resolved information;
- temporally resolved information on a time scale of longer than about one microsecond;
- temporally resolved information on a sub one hundred picosecond timeframe;
- incident photon angle information;
- photon collection angle information;
- interrelationships of spectral absorbance and/or intensity information;
- environmental information;
- temperature information; and
- information related to contact pressure on a tissue sample site.
In still yet another embodiment, a temporal resolution gating noninvasive analyzer is used to determine an analyte property of a biomedical sample, such as a glucose concentration of a subject using light in the near-infrared region from 1000 to 2500 nanometers.
AxesHerein, axes systems are separately defined for an analyzer and for an interface of the analyzer to a patient, where the patient is alternatively referred to as a subject.
Herein, when referring to the analyzer, an x, y, z-axes analyzer coordinate system is defined relative to the analyzer. The x-axis is the in the direction of the mean optical path. The y-axis crosses the mean optical path perpendicular to the x-axis. When the optical path is horizontal, the x-axis and y-axis define a x/y horizontal plane. The z-axis is normal to the x/y plane. When the optical path is moving horizontally, the z-axis is aligned with gravity, which is normal to the x/y horizontal plane. Hence, the x, y, z-analyzer coordinate system is defined separately for each optical path element. If necessary, where the mean optical path is not horizontal, the optical system is further defined to remove ambiguity.
Herein, when referring to the patient, an x, y, z-axes patient coordinate system is defined relative to a body part interfaced to the analyzer. Hence, the x, y, z-axes body coordinate system moves with movement of the body part. The x-axis is defined along the length of the body part, the y-axis is defined across the body part. As an illustrative example, if the analyzer interfaces to the forearm of the patient, then the x-axis runs longitudinally between the elbow and the wrist of the forearm and the y-axis runs across the forearm. Together, the x,y plane tangentially touches the skin surface at a central point of the interface of the analyzer to the body part, which is referred to as the center of the sample site, sample region, or sample site. The z-axis is defined as orthogonal to the x,y plane. Rotation of an object is further used to define the orientation of the object to the sample site. For example, in some cases a sample probe of the analyzer is rotatable relative to the sample site. Tilt refers to an off z-axis alignment, such as an off z-axis alignment of a probe of the analyzer relative to the sample site.
AnalyzerReferring now to
Still referring to
Still referring to
Still referring to
Still referring to
Still referring to
Herein, the source system 110 generates photons in any of the visible, infrared, near-infrared, mid-infrared, and/or far-infrared spectral regions. In one case, the source system generates photons in the near-infrared region from 1100 to 2500 nm or any range therein, such as within the range of about 1200 to 1800 nm; at wavelength longer than any of 800, 900, 1000, and 1100 nm; and/or at wavelengths shorter than any of 2600, 2500, 2000, or 1900 nm.
Photon/Skin InteractionLight interacts with skin through laws of physics to scatter and transmit through skin voxels.
Referring now to
Referring still to
Herein, for clarity, without loss of generality, and without limitation, Beer's Law is used to described photon interaction with skin, though those skilled in the art understand deviation from Beer's Law result from sample scattering, index of refraction variation, inhomogeneity, turbidity, and/or absorbance out of a linear range of the analyzer 100.
Beer's Law, equation 1, states that:
AαbC (eq. 1)
where A is absorbance, b is pathlength, and C is concentration. Typically, spectral absorbance is used to determine concentration. However, the absorbance is additionally related to pathlength. Hence, determination of the optical pathlength traveled by the photons is useful in reducing error in the determined concentration. Two methods, described infra, are optionally used to estimate pathlength: (1) spatial resolution of pathlength and (2) temporal resolution of pathlength.
AlgorithmThe data and/or derived information from each of the spatial resolution method and temporal resolution method are each usable with the data processing system 140. Examples provide, infra, illustrate: (1) both cases of the spatial resolution method and (2) the temporal resolution method. However, for clarity of presentation and without limitation, the photons in most examples are depicted as radially traversing from a range of input zones to a detection zone. Similarly, photons are optionally delivered, simultaneously and/or as a function of time, from an input zone to a range of detection zones. Still further, photons are optionally directed to a series of input zones, as a function of time, and one or more detection zones are used to detect the photons directed to the series of input zones, simultaneously and/or as a function of time.
Spatial ResolutionThe first method of spatial resolution contains two cases. Herein, in a first case photons are depicted traversing from a range of input points on the skin to a radially located detector to derive photon interrogated sample path and/or depth information. However, in a second case, similar systems optionally use a single input zone of the photons to the skin and a plurality of radially located detector zones to determine optical sample photons paths and/or depth information. Still further, a combination of the first two cases, such as multiple sources and multiple detectors, is optionally used to derive photon path information in the skin.
In the first system, Referring now to
In the first case of the spatial resolution method, referring now to
In the second case of the spatial resolution method, referring now to
Referring again to
The second method of temporal resolution is optionally performed in a number of manners. For clarity of presentation and without limitation, a temporal resolution example is provided where photons are timed using a gating system and the elapsed time is used to determine photon paths in tissue.
Referring now to
where OPD is the optical path distance, c is the speed of light, n is the index of refraction of the sample, and b is the physical pathlength. Optionally, n is a mathematical representation of a series of indices of refraction of various constituents of skin and/or skin and surrounding tissue layers. More generally, observed pathlength is related to elapsed time between photon launch and photon detection where the pathlength of photons in the sample is related to elapsed time, optionally with one or more additional variables related to one or more refractive indices.
Referring now to
Referring now to
Referring now to
Hence, both the spatial resolution method and temporal resolution method yield information on pathlength, b, which is optionally used by the data processing system 140 to reduce error in the determined concentration, C.
Analyzer and Subject VariationAs described, supra, Beer's Law states that absorbance, A, is proportional to pathlength, b, times concentration, C. More precisely, Beer's Law includes a molar absorbance, ε, term, as shown in equation 3:
A=εbC (eq. 3)
Typically, spectroscopists consider the molar absorbance as a constant due to the difficulties in determination of the molar absorbance for a complex sample, such as skin of the subject 170. However, information related to the combined molar absorbance and pathlength product for skin tissue of individuals is optionally determined using one or both of the spatially resolved method and time resolved method, described supra. In the field of noninvasive glucose concentration determination, the product of molar absorbance and pathlength relates at least to the dermal thickness of the particular individual or subject 170 being analyzed. Examples of spatially resolved analyzer methods used to provide information on the molar absorbance and/or pathlength usable in reduction of analyte property estimation or determination are provided infra.
Spatially Resolved AnalyzerHerein, an analyzer 100 using fiber optics is used to describe obtaining spatially resolved information, such as pathlength and/or molar absorbance, of skin of an individual, which is subsequently used by the data processing system 140. The use of fiber optics in the examples is used without limitation, without loss of generality, and for clarity of presentation. More generally, photons are delivered in quantities of one or more through free space, through optics, and/or off of reflectors to the skin of the subject 170 as a function of distance from a detection zone.
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
Still referring to
Still referring to
In practice, the mask wheel 830 contains an integral number of n positions, where the n positions selectively illuminate and/or block any combination of: (1) the individual fibers of the set of fiber optics 713 and/or (2) bundlets 810 of the set of fiber optic optics 713. Further, the filter wheel is optionally of any shape and uses any number of motors to position mask position openings relative to selected fiber optics. Still further, in practice the filter wheel is optionally any electro-mechanical and/or electro-optical system used to selectively illuminate the individual fibers of the set of fiber optics 713. Yet still further, in practice the filter wheel is optionally any illumination system that selectively passes light to any illumination optic or illumination zone, where various illumination zones illuminate various regions of the subject 170 as a function of time. The various illumination zones alter the effectively probed sample site 178 or region of the subject 170.
Radial Position Using a Mirror and/or Lens System
Referring now to
Referring now to
Still more generally, the data processing system 140 and/or the system controller 180 optionally control one or more optics, figuratively illustrated as the mirror 1010, to dynamically control incident light 711 on the subject 170 relative to a detection zone on the subject 170 that combine to form the sample site 178 through control of one or more of:
-
- x-axis position of the incident light on the subject 170;
- y-axis position of the incident light on the subject 170;
- solid angle of the incident light on a single fiber of the fiber bundle 710;
- solid angle of incident light on a set of fibers of the fiber bundle 710;
- a cross-sectional diameter or width of the incident light;
- an incident angle of the incident light on the subject 170 relative to an axis perpendicular to skin of the subject 170 where the incident light interfaces to the subject 170;
- focusing of the incident light; and/or
- depth of focus of the incident light on the subject 170.
Several examples are provided, infra, to further illustrate the use of the system controller 180 to control shape, position, and/or angle of the incident light 711 reaching a fiber optic bundle, skin of the subject 170, and/or an element of the photon transport system 120.
Referring again to
Referring now to
Referring now to
Referring now to
Delivery of the incident light 711 to the subject 170 is optionally varied in time in terms of position, radial position relative to a point of the skin of the subject 170, solid angle, incident angle, depth of focus, energy, and/or intensity. Herein, without limitation a spatial illumination system is used to illustrate the controlled and variable use of incident light.
Referring now to
Referring now to
Referring now to
In yet another example, light is delivered with known radial distance to the detection zone, such as with optics of the analyzer, without use of a fiber optic bundle and/or without the use of a filter wheel. Just as the illumination ring determines the deepest tissue layer probed, control of the irradiation zone/detection zone distance determines the deepest tissue layer probed.
Incident Light ControlReferring again to
-
- delivery of the incident light 711 to a single selected fiber optic of the fiber optic bundle 710;
- delivery of the incident light 711 to a selected bundlet of the set of fiber optic bundlets 810, such as to the first bundlet 811 at a first point in time and to the second bundlet 812 at a second point in time;
- variation of solid angle of the incident light 711 to an optic and/or to the subject 170;
- variation of radial position of delivery of the incident light 711 relative to a fixed location, such as a center of an optic, a target point on skin of the subject 170, or a center of the sample site 178;
- incident angle of the incident light 711 relative to a plane tangential to the skin of the subject 170 and/or an axis normal to the skin of the subject 170 at the sample site 178;
- apparent focus depth of the incident light 711 into the skin of the subject 170;
- energy; and
- intensity, such as number of photon per second varying from one point in time to another by greater than 1, 10, 50, 100, 500, 1000, or 5000 percent.
In still yet another example, referring again to time resolved spectroscopy, instead of delivering light through the filter wheel to force radial distance, photons are optionally delivered to the skin and the time resolved gating system is used to determine probably photon penetration depth. For example, Table 3 shows that at greater elapsed time to the nth gated detection period, the probability of the deepest penetration depth reaching deeper tissue layers increases.
Referring now to
Referring now to
In a first example, referring again to
In a second example, a first spectral marker is optionally related to the absorbance of the subcutaneous fat 176 for the first subject 171. During the first sample mapping phase 1310, the fifth and sixth radial positions of the fiber probe illustrated in
In a third example, the first sample mapping phase 1310 of the previous example is repeated for the second subject 172. The first sample mapping phase 1310 indicates that for the second subject, the sixth radial illumination ring of the fiber bundle illustrated in
In a fourth example, the first mapping phase 1310 determines positions on the skin where papillary dermis ridges are closest to the skin surface and positions on the skin where the papillary dermis valleys are furthest from the skin surface. In the subsequent subject specific data collection phase 1330, the incident light is optionally targeted at the papillary dermis valleys, such as greater than 50, 60, or 70 percent of the incident light is targeted at the papillary dermis valley and less than 30, 40, or 50 percent of the incident light is targeted at the papillary dermis ridge. The increased percentage of the incident light striking the papillary dermis valley increases the number of photons sampling the underlying dermis layer, where blood borne analytes reside, which increases the signal-to-noise ratio of collected data and lowers resultant errors in blood borne analyte property determination.
Generally, a particular subject is optionally probed in a sample mapping phase 1310 and results from the sample mapping phase 1310 are optionally used to configure analyzer parameters in a subsequent subject specific data collection phase 1330. While for clarity of presentation, and without loss of generality, radial distance was varied in the provided examples, any optical parameter of the analyzer is optionally varied in the sample mapping phase 1310, such as sample probe position, incident light solid angle, incident light angle, focal length of an optic, position of an optic, energy of incident light, and/or intensity of incident light. Optionally, the sample mapping phase 1310 and sample specific data collection phase 1330 occur within thirty seconds of each other. Optionally, the subject 170 does not move away from the sample interface 150 between the sample mapping phase 1310 and the subject specific data collection phase 130. Further, generally each of the spatial and temporal methods yield information on pathlength, b, and/or a product of the molar absorptivity and pathlength, which is not achieved using a standard spectrometer.
In yet another embodiment, the sample interface tip 716 of the fiber optic bundle 710 includes optics that change the mean incident light angle of individual fibers of the fiber optic bundle 716 as they first hit the subject 170. For example, a first optic at the end of a fiber in the first ring 741 aims light away from the collection fiber optic 718; a second optic at the end of a fiber in the second ring 742 aims light nominally straight into the sample; and a third optic at the end of a fiber in the third ring 742 aims light toward the collection fiber 718. Generally, the mean direction of the incident light varies by greater than 5, 10, 15, 20, or 25 degrees.
Data Processing SystemThe data processing system 140 is further described herein. Generally, the data processing system uses an instrument configuration analysis system 1340 to determine an optical configuration of the analyzer 100 and/or a software configuration of the analyzer 100 while the sample property analysis system 1350 is used to determine a chemical, a physical, and/or a medical property, such as an analyte concentration, measured or represented by collected spectra. Further, the data processing system 140 optionally uses a preprocessing step and a processing step to determine an instrument configuration and/or to determine an analyte property.
In one embodiment, the data processing system 140 uses a preprocessing step to achieve any of: lower noise and/or higher signal. Representative and non-limiting forms of preprocessing include any of: use of a digital filter, use of a convolution function, use of a derivative, use of a smoothing function, use of a resampling algorithm, and/or a form of assigning one or more spectra to a cluster of a whole. The data processing system subsequently uses any multivariate technique, such as a form of principal components regression, a form of partial least squares, and/or a form of a neural network to further process the pre-processed data.
In another embodiment, the data processing system 140 and/or the sample property analysis system 1350 operates on spectra collected by the analyzer 100, such as in the subject specific data collection phase 1330, using a first step of defining finite width channels and a second step of feature extraction, which are each further described, infra.
Finite Width ChannelsIn one example, the sample property analysis system 1350 defines a plurality of finite width channels, where the channels relate to changes in an optical parameter, software setting of the analyzer 100, a chemical condition, a physical property, a distance, and/or time. Still further, the channels optionally relate to radial distance between the incident light from the analyzer 100 entering skin of the subject 170 and detected light exiting the skin of the subject 170 and detected by the detector system 130, a focal length of an optic, a solid-angle of a photon beam from the source system 110, an incident angle of light onto skin of the subject, and/or a software setting, such as control over spectral resolution. For clarity of presentation, the channels are described herein in terms of wavelength channels. For example, a spectrum is collected over a range of wavelengths and the finite width channels represent finite width wavelength channels within the spectrum. Generally, the channels are processed to enhance localized signal, to decrease localized noise, and/or are processed using a cross-wavelet transform.
In one case, the sample property analysis system 1350 defines a plurality of finite width wavelength channels, such as more than 3, 5, 10, 15, 20, 30, 40, or 50 wavelength channels contained in a broader spectral region, such as within a spectrum from 900 to 2500 nanometers or within a sub-range therein, such as within 1100 to 1800 nanometers. The plurality of multiple finite width wavelength channels enhance accessibility to content related to: (1) a target analyte, such as a glucose concentration, and (2) a measurement context, such as the state of skin of the subject 170, which is used as information in a self-correcting background.
Feature ExtractionIn one case, feature extraction determines and/or calculates coherence between channels, which is referred to herein as cross-coherence, to identify and/or enhance information common to the analytical signal, such as frequency, wavelength, shift, and/or phase information. Subsequently, cross-coherence terms are selected using a metric, such as to provide maximum contrast between: (1) the target analyte or signal and (2) the measurement context or background. Examples of background include, but are not limited to: spectral interference, instrument drift impacting the acquired signal, spectral variation resultant from physiology and/or tissue variation, temperature impact on the analyzer, mechanical variations in the analyzer as a function of time, and the like. Generally, the cross-coherence terms function to reduce toward or to monotonicity detected variation as a function of analyte concentration. In a particular instance, an N×N grid is generated per spectrum, which is symmetric about the diagonal of the N×N grid, with each grid element representing an M term coherence estimate versus frequency, where N is a positive integer of at least three.
ModelTypically, a model, such as a nonlinear model, is constructed to map the extracted features to the analyte property, such as a glucose concentration. For example, the total differential power of the cross-coherence estimate is determined between features related to the analyte versus the background and a separate nonlinear function is calculated for multiple analyte ranges.
Absorbance SpectraThe data processing system 140 optionally uses absorbance spectra of skin and/or blood constituents, such as water absorbance peaks at about 1450 nm or in the range of 1350 to 1500 nm.
In one example, a method for determining a concentration of a blood borne analyte of a subject, includes the steps of: (1) collecting a plurality of mapping spectra of the subject using a noninvasive analyzer setup in a first set of optical configurations, (2) calculating a metric related to skin tissue physiology of the subject using the mapping spectra, (3) based on the metric, setting up the analyzer in a second set of optical configurations, the first set of optical configurations is configured to deliver light to the subject in a manner different than the second set of optical configurations, (4) collecting subject specific noninvasive spectra of the subject using the second set of optical configurations; and (5) post-processing the subject specific noninvasive spectra to determine the concentration.
Still yet another embodiment includes any combination and/or permutation of any of the analyzer and/or sensor elements described herein.
The particular implementations shown and described are illustrative of the invention and its best mode and are not intended to otherwise limit the scope of the present invention in any way. Indeed, for the sake of brevity, conventional manufacturing, connection, preparation, and other functional aspects of the system may not be described in detail. Furthermore, the connecting lines shown in the various figures are intended to represent exemplary functional relationships and/or physical couplings between the various elements. Many alternative or additional functional relationships or physical connections may be present in a practical system.
In the foregoing description, the invention has been described with reference to specific exemplary embodiments; however, it will be appreciated that various modifications and changes may be made without departing from the scope of the present invention as set forth herein. The description and figures are to be regarded in an illustrative manner, rather than a restrictive one and all such modifications are intended to be included within the scope of the present invention. Accordingly, the scope of the invention should be determined by the generic embodiments described herein and their legal equivalents rather than by merely the specific examples described above. For example, the steps recited in any method or process embodiment may be executed in any order and are not limited to the explicit order presented in the specific examples. Additionally, the components and/or elements recited in any apparatus embodiment may be assembled or otherwise operationally configured in a variety of permutations to produce substantially the same result as the present invention and are accordingly not limited to the specific configuration recited in the specific examples.
Benefits, other advantages and solutions to problems have been described above with regard to particular embodiments; however, any benefit, advantage, solution to problems or any element that may cause any particular benefit, advantage or solution to occur or to become more pronounced are not to be construed as critical, required or essential features or components.
As used herein, the terms “comprises”, “comprising”, or any variation thereof, are intended to reference a non-exclusive inclusion, such that a process, method, article, composition or apparatus that comprises a list of elements does not include only those elements recited, but may also include other elements not expressly listed or inherent to such process, method, article, composition or apparatus. Other combinations and/or modifications of the above-described structures, arrangements, applications, proportions, elements, materials or components used in the practice of the present invention, in addition to those not specifically recited, may be varied or otherwise particularly adapted to specific environments, manufacturing specifications, design parameters or other operating requirements without departing from the general principles of the same.
Although the invention has been described herein with reference to certain preferred embodiments, one skilled in the art will readily appreciate that other applications may be substituted for those set forth herein without departing from the spirit and scope of the present invention. Accordingly, the invention should only be limited by the Claims included below.
Claims
1. A method for determining a concentration of a blood borne analyte of a subject, comprising the steps of:
- collecting a plurality of mapping spectra of the subject using a noninvasive analyzer setup in a first set of optical configurations;
- calculating a metric related to skin tissue physiology of the subject using the mapping spectra;
- based on the metric, setting up said analyzer in a second set of optical configurations, the first set of optical configurations configured to deliver light to the subject in a manner different than the second set of optical configurations;
- collecting subject specific noninvasive spectra of the subject using the second set of optical configurations; and
- post-processing the subject specific noninvasive spectra to determine the concentration.
2. The method of claim 1, wherein said step of collecting a plurality of mapping spectra comprises the step of:
- tilting an optic of said analyzer to at least three orientations and collecting the mapping spectra sequentially at each of the at least three orientations of the optic.
3. The method of claim 1, wherein said step of collecting a plurality of mapping spectra comprises the step of:
- sequentially collecting a set of spectra using at least three different mean radial distances between incident light from said analyzer entering skin of the subject and a detection zone of detected light exiting the skin of the subject to a detector system of said analyzer, wherein the three different mean radial distances differ from each other by at least ten micrometers, wherein the three mean radial distances are each less than one millimeter.
4. The method of claim 1, wherein said step of collecting a plurality of mapping spectra comprises the step of:
- sequentially collecting a set of spectra using at least three different mean radial distances between incident light from said analyzer entering skin of the subject and a detection zone of detected light exiting the skin of the subject to a detector system of said analyzer, wherein the three different mean radial distances differ from each other by at least one-fifth of a millimeter, wherein the three mean radial distances are each less than four millimeters.
5. The method of claim 4, wherein said step of calculating a metric related to skin tissue physiology comprises any of the steps of:
- generating an epidermal thickness measure of the skin tissue physiology;
- generating a dermis thickness measure of the skin tissue physiology; and
- generating a subcutaneous fat depth measure of the skin tissue physiology.
6. The method of claim 4, wherein said step of calculating a metric related to skin tissue physiology comprises any of the steps of:
- calculating a measure of pathlength through an aqueous medium;
- calculating a measure of pathlength through a fat medium; and
- calculating a measure of signal-to-noise ratio for any of the set of spectra at the at least three different mean radial distances.
7. The method of claim 4, wherein said step of setting up said analyzer in the second set of optical configurations increases mean absorbance of spectra with any of: (1) a range of 1325 to 1375 nm, (2) a range of 1375 to 1425 nm, (3) a range of 1425 to 1475, and (4) a range of 1475 to 1525 nanometers by at least ten percent relative to absorbance collected using the first set of optical configurations.
8. The method of claim 4, wherein said step of setting up said analyzer in the second set of optical configurations increases an average absorbance ratio of spectra at 1450 nanometers to that at 1720 nanometers relative to the mapping spectra using the first set of optical configurations.
9. The method of claim 4, wherein a mean range of radial distance between the incident light entering the skin and the collected light exiting the skin is greater for said plurality of mapping spectra than for the subject specific noninvasive spectra.
10. The method of claim 1, wherein the plurality of mapping spectra comprise spectra collected in more optical configurations of said analyzer than used to collect the subject specific noninvasive spectra.
11. The method of claim 1, said step of post-processing further comprising the step of:
- determining correlation between two non-overlapping wavelength ranges of the subject specific noninvasive spectra.
12. The method of claim 1, said step of post-processing further comprising the steps of:
- defining finite width channels for the noninvasive spectra;
- calculating coherence between the channels to form a set of cross-coherence values; and
- selecting a subset of the set of cross-coherence values for subsequent multivariate analysis.
13. The method of claim 1, said step of post-processing further comprising the step of:
- generating a N×N grid of at least one spectrum of the subject specific noninvasive spectra, symmetrical about a diagonal of the N×N grid, wherein elements of the N×N grid represent a coherence estimate versus frequency, wherein N comprises a positive integer of at least ten.
14. The method of claim 1, further comprising the step of:
- using a model and said metric in said step of setting up said analyzer.
15. An apparatus for determining a concentration of a blood borne analyte of a subject, comprising:
- a noninvasive analyzer, comprising: a source configured to provide photons; a photon transport system configured to deliver the photons to the subject; and a detector system configured to receive the photons from the subject, said analyzer configured to collect a plurality of mapping spectra of the subject using said analyzer in a first set of optical configurations; and
- a data processing system, said data processing system configured to: calculate a metric related to skin tissue physiology of the subject using the mapping spectra; and set up said analyzer in a second set of optical configurations, the first set of optical configurations configured to deliver light to the subject in a manner different than the second set of optical configurations,
- said analyzer configured to collect subject specific noninvasive spectra of the subject using the second optical configuration, and
- said data processing system configured to post-process the subject specific noninvasive spectra to determine the concentration.
16. The apparatus of claim 15, said analyzer further comprising:
- a tiltable optic, said tiltable optic configured in at least three distinct orientations during collection of the mapping spectra.
17. The apparatus of claim 15, said analyzer further comprising:
- means for sequentially collecting a set of spectra using at least three different mean radial distances between incident light from said source entering skin of the subject and a detection zone of detected light exiting the skin of the subject to said detector system, wherein the three different mean radial distances differ from each other by at least one-half millimeter, wherein the three mean radial distances are each less than four millimeters.
18. The apparatus of claim 15, said analyzer comprising:
- a set of at least three fiber optics at at least three radial positions from a mean position of photons exiting the subject into said detector system; and
- a photon delivery system configured to individually and sequentially illuminate each of said set of at least three fiber optics with the photons from said source.
19. The apparatus of claim 15, said photon transport system comprising:
- at least one optic configured to deliver a mean path of the photons to the subject at at least three positions separated from each other by at least one-twentieth of a millimeter as a function of time.
20. The apparatus of claim 15, said photon transport system comprising:
- at least one optic configurable to at least three focal lengths as a function of time.
21. The apparatus of claim 15, said analyzer further comprising:
- a time resolved gating system configured to detect the photons in a pulse mode from the source in time periods greater than one femtosecond and less than one hundred milliseconds after the photons leave the source.
22. The apparatus of claim 15, said photon transport system comprising:
- at least one optic configurable to deliver the photons to the subject, during a single sampling period of less than one minute, at at least three mean incident angles relative to a plane normal to the subject, wherein the at least three mean incident angles differ from each other by greater than five degrees as a function of time.
23. The apparatus of claim 15, said data processing system configured to:
- calculate a set of coherence values between finite width channels of elements of the noninvasive spectra; and
- use said set of coherence values in determination of the concentration of the blood borne analyte of the subject.
Type: Application
Filed: Jul 12, 2013
Publication Date: Jan 15, 2015
Inventors: Sandeep Gulati (La Canada, CA), Thomas George (La Canada, CA), Timothy Ruchti (Gurnee, IL), Alan Abul-Haj (Mesa, AZ), Kevin H. Hazen (Gilbert, AZ)
Application Number: 13/941,411
International Classification: A61B 5/1455 (20060101); A61B 5/145 (20060101); A61B 5/107 (20060101);